Last reviewed · How we verify
Grass pollen specific immunotherapy
Grass pollen specific immunotherapy desensitizes the immune system to grass pollen allergens by gradually introducing increasing doses to induce immune tolerance.
Grass pollen specific immunotherapy desensitizes the immune system to grass pollen allergens by gradually introducing increasing doses to induce immune tolerance. Used for Grass pollen-induced allergic rhinitis and/or allergic asthma.
At a glance
| Generic name | Grass pollen specific immunotherapy |
|---|---|
| Sponsor | Allergopharma GmbH & Co. KG |
| Drug class | Allergen immunotherapy |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
This immunotherapy works by administering gradually increasing doses of grass pollen extract to shift the immune response from IgE-mediated allergic reactions toward protective IgG and regulatory T cell responses. Over time, this process reduces allergic sensitivity and clinical symptoms upon natural grass pollen exposure. The mechanism involves both central tolerance induction and peripheral immune regulation.
Approved indications
- Grass pollen-induced allergic rhinitis and/or allergic asthma
Common side effects
- Local injection site reactions (itching, swelling, erythema)
- Oral allergy syndrome (itching/swelling of mouth and throat)
- Systemic allergic reactions
- Rhinitis symptoms
- Asthma exacerbation
Key clinical trials
- Identification of B Regulatory Cells by Flow Cytometry
- Safety of Bronchial Allergen Challenge and Predictors for Positive Reaction. (NA)
- Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Grass Pollen Allergy Vaccine (PHASE2)
- Different Doses of Tyrosine Adsorbed Grass Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Grass Pollen (PHASE2)
- Influence of Specific Immunotherapy With Pollinex Quattro (Tree-/Grass Pollen) on Allergen-specific Immunoglobulin E (IgE) Levels
- Safety and Efficacy Study of Intralymphatic Allergen-specific Immunotherapy (PHASE2, PHASE3)
- Safety of Lymph Node Injection for Allergen Immunotherapy (PHASE1)
- Skin Test Study of BM32 (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |